Positive Study Results from Biogen on Nusinersen for SMA
Biogen Inc. (Nasdaq: BIIB) has recently shared some promising topline results from their pivotal Phase 2/3 DEVOTE study. This research focused on a new higher dose regimen of nusinersen, aimed at treating spinal muscular atrophy (SMA) in infants diagnosed with the condition. The findings indicate significant potential, suggesting that this new dosing approach could greatly enhance treatment options for SMA.
Study Design and Findings
The Part B cohort of the Phase 2/3 DEVOTE study involved infants with symptomatic SMA who had not yet received treatment. Central to this study was the higher dose regimen for nusinersen, which features an accelerated loading phase consisting of two 50 mg doses given 14 days apart, followed by a maintenance dose of 28 mg every four months. This new regimen is being compared to the currently approved dose of 12 mg of nusinersen, known as SPINRAZA.
Within the first six months, the study met its primary endpoint, showing a statistically significant improvement in motor function among infants receiving the higher dose regimen when compared to a matched sham control group. Those who received the new higher dose regimen achieved a least squares mean difference score of 26.19 on the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) test, highlighting a remarkable enhancement.
Implications for SMA Treatment
“While we have made significant progress in managing SMA, there is still a substantial unmet need,” stated Stephanie Fradette, Pharm.D., who leads Biogen's Neuromuscular Development Unit. The study supports the idea that a higher dose of nusinersen could potentially accelerate the reduction of neurodegeneration, as evidenced by decreased neurofilament levels observed by day 64 post-treatment. Over time, this regimen appears to offer considerable clinical benefits for infants suffering from symptomatic SMA.
Overview of the DEVOTE Study
The DEVOTE study is extensive, comprising three parts and enrolling 145 participants from various age groups and SMA types. The pivotal Part B included 75 infants who were randomly assigned to either the investigational higher dose regimen or the approved 12 mg regimen, which consists of four loading doses followed by maintenance treatments. Results consistently favored the higher dose not only regarding the primary endpoint but also in several selected secondary endpoints, where positive trends were noted. Additionally, safety monitoring revealed that serious adverse events were less common in the higher dose group.
About SPINRAZA
SPINRAZA has emerged as a cornerstone treatment for SMA, having received approval in over 71 countries and benefiting more than 14,000 patients worldwide. This therapy, classified as an antisense oligonucleotide, addresses the underlying motor neuron loss by boosting the production of survival motor neuron (SMN) protein. SPINRAZA is delivered directly into the central nervous system, effectively targeting the root cause of SMA. Extensive clinical monitoring over the years has confirmed its safety and efficacy across diverse demographics, highlighting its critical role in the SMA care continuum.
Future Directions
Biogen is dedicated to sharing more detailed data with the broader SMA community and regulatory bodies in the upcoming months, showcasing the transformative potential of their investigational higher dose regimen of nusinersen. These advancements may pave the way for improved treatment protocols that could significantly enhance the quality of life for individuals affected by this challenging condition.
Frequently Asked Questions
What is the main finding of Biogen's DEVOTE study?
The study found that a higher dose regimen of nusinersen significantly improved motor function in infants with SMA compared to an untreated control group.
How does the new dosing regimen of nusinersen compare to the approved dose?
The new regimen consists of two higher doses followed by a higher maintenance dose, which contrasts with the previously approved dosage that maintained a 12 mg administration schedule.
What impact does the new dosing have on treatment timelines?
The accelerated loading doses aim to provide earlier and potentially more pronounced clinical benefits, reducing neurological deterioration more quickly in infants diagnosed with SMA.
What is SPINRAZA and how does it function?
SPINRAZA is an FDA-approved therapy designed to treat SMA by increasing the production of survival motor neuron (SMN) protein, delivered directly into the central nervous system.
When can we expect more information on the DEVOTE study results?
More comprehensive results from the DEVOTE study are expected to be presented at upcoming medical conferences, providing greater insight into the efficacy and safety of the higher dose regimen.
